Lung Cancer

Adjuvant pembrolizumab continued to extend DFS in resected stage IB to IIIA NSCLC, though OS did not differ from placebo.

Longer DeLLphi-304 follow-up showed sustained OS, PFS, and response durability with tarlatamab in second-line small cell lung cancer.

Izalontamab brengitecan improved progression-free survival vs chemotherapy in EGFR-mutated lung cancer after a third-generation EGFR inhibitor.

Frontline savolitinib plus osimertinib improved progression-free survival vs osimertinib alone in EGFR-mutated, MET-overexpressing lung cancer.

In SAFFRON, the oral EGFR/MET inhibitor pairing extended survival over platinum/pemetrexed in MET-driven lung cancer that progressed on osimertinib.

Adding LK101 to tislelizumab-based first-line maintenance yielded early antitumor activity and signs of immune activation in advanced NSCLC.

Adding tarlatamab-dlle to durvalumab maintenance extended survival in extensive-stage small cell lung cancer in the phase 3 DeLLphi-305 trial.

Circulating tumor DNA findings from CROWN tied TP53 status and tumor fraction to outcomes with first-line lorlatinib in ALK-positive lung cancer.

Readers share their opinions on some of the most talked-about lung cancer abstracts they’re looking forward to seeing at ESMO 2026.

Thoracic oncologists weigh how TROP2-directed antibody-drug conjugates fit into sequencing and combination strategies for EGFR-mutated NSCLC.

Faculty at an OncLive Scientific Interchange and Workshop discussed individualizing frontline immune checkpoint inhibitor selection in metastatic NSCLC.

The CHMP opinion supports 700 mg every 6 weeks after 12 weeks of 350 mg every 3 weeks; a European Commission decision is expected in the coming months.

Read on to see which data are poised to shape clinical discussions and decision-making in lung cancer at the 2026 ESMO Congress in Madrid, Spain.

Invikafusp alfa now holds fast track status across TMB-H solid tumors that progressed after prior therapy, including checkpoint inhibition.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Experts break down key lung cancer data and trends from the IASLC 2026 World Conference on Lung Cancer.

Here is your cheat sheet to all therapeutic options that were cleared by the FDA in September 2026 spanning tumor types.

The c-Met–directed ADC was designated for EGFR wild-type nonsquamous NSCLC after platinum chemotherapy and anti–PD-(L)1 therapy.

Firmonertinib did not significantly improve BICR-assessed PFS vs platinum/pemetrexed chemotherapy in first-line EGFR exon 20–mutant NSCLC in FURVENT trial.

Lung cancer experts discuss emerging strategies after immunotherapy in advanced squamous NSCLC, including updated PRESERVE-003 data from WCLC 2026.

The FDA approved pirtobrutinib for untreated chronic lymphocytic leukemia, granted priority review to elinzanetant for breast cancer hot flashes, and more.

TRE-515 earned fast track status in combination with KRAS inhibitors for G12C-mutated NSCLC after anti–PD-(L)1 therapy and platinum-based chemotherapy.

An NDA for zipalertinib in EGFR exon 20 insertion–positive NSCLC is being supported by phase 3 REZILIENT3 data.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

In case you missed any, read a recap of the episodes of OncLive On Air that aired in September 2026.